98%
921
2 minutes
20
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s13312-025-00174-7 | DOI Listing |
BMC Neurol
September 2025
Department of Neurology, University Hospital Schleswig-Holstein, Kiel, Germany.
Background: Parkinson's disease (PD) is characterized by motor symptoms altering gait domains such as slow walking speed, reduced step and stride length, and increased double support time. Gait disturbances occur in the early, mild to moderate, and advanced stages of the disease in both backward walking (BW) and forward walking (FW), but are more pronounced in BW. At this point, however, no information is available about BW performance and disease stages specified using the Hoehn and Yahr (H&Y) scale.
View Article and Find Full Text PDFBMC Public Health
September 2025
Division of Insurance Medicine, Department of Clinical Neuroscience, Karolinska Institutet, 171 77, Stockholm, Sweden.
Background: As populations age, more knowledge is needed on people who extend their working lives. The aim of this study was to explore if prior sickness absence (> 14 days) and/or disability pension (SADP) in mental and/or somatic diagnoses were associated with time until work exit after ages 65-69 and ≥ 70, respectively, among women and men.
Methods: This prospective population-based cohort study included all 65-69-year-olds (cohort65, n = 201,263) and ≥ 70-year-olds (cohort70, n = 93,751) who were in paid work in Sweden in 2014.
Eur J Clin Pharmacol
September 2025
Department of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
Objective: This research aimed at evaluating the effectiveness and safety of nitazoxanide and escitalopram as adjuvant therapies in patients with rheumatoid arthritis (RA).
Methods: In this randomized controlled parallel study, 90 patients with active RA were randomized into three groups; group 1 (control group; n = 30) which received traditional therapy, group 2 (Nitazoxanide group; n = 30) which received traditional therapy plus 1 gm/day oral nitazoxanide, and group 3 (Escitalopram group; n = 30) which received traditional therapy plus 10 mg/day oral escitalopram for three months. At baseline and 3 months after treatment, clinical and functional assessments were done through the 28-joint count disease activity score using C-reactive protein (DAS28-CRP), the health assessment questionnaire-disability index (HAQ-DI), and the patient's global assessment (PGA).
Dev Med Child Neurol
September 2025
International Centre for Evidence in Disability, London School of Hygiene & Tropical Medicine, London, UK.
JMIR Res Protoc
September 2025
Moores Cancer Center, University of California, San Diego, La Jolla, CA, United States.
Background: Cancer screening nonadherence persists among adults who are deaf, deafblind, and hard of hearing (DDBHH). These barriers span individual, clinician, and health care system levels, contributing to difficulties understanding cancer information, accessing screening services, and following treatment directives. Critical communication barriers include ineffective patient-physician communication, limited access to American Sign Language (ASL) cancer information, misconceptions about medical procedures, insurance navigation difficulties, and intersectional barriers for multiply marginalized individuals.
View Article and Find Full Text PDF